In adult HIV patients on ART who have noninfectious diarrhea
Mytesi (crofelemer) is the only antidiarrheal studied in and FDA-approved for relief of diarrhea in adults living with HIV/AIDS.
- Mytesi treats diarrhea differently by normalizing the flow of water in the GI tract
- Mytesi is not an opioid and does not affect GI motility
Mytesi has been proven to have:
- Minimal absorption, with plasma concentrations below the level of detection
- No clinically relevant drug-drug interactions
- No effect on viral load or CD4 counts
- Adverse events comparable to those with placebo
Important Safety Information about Mytesi
Mytesi is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).
Please see Full Prescribing Information at Mytesi.com